Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
NCT01546415Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2011
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deferasirox in iron overload, sponsored by Novartis. Primary endpoint: Change in serum ferritin from baseline to 52 weeks. Started Oct 2011; status: completed.
02
Drugs
deferasirox
03
Conditions
iron overload
Beyond the preview
Go deeper on NCT01546415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01546415.